Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?

Encompass Health (EHC) shares have demonstrated significant outperformance, reaching a new 52-week high of $123.9, with a 13.6% gain over the past month and 33.8% year-to-date, considerably surpassing its sector and industry benchmarks. This momentum is attributed to a consistent track record of earnings surprises, including a recent EPS of $1.4 against a $1.2 consensus, and strong fiscal year projections, with EPS growth anticipated at 18.28%. While trading at a premium 23.6x current fiscal year EPS estimates compared to peers, EHC holds a Zacks Rank #2 (Buy) based on positive analyst revisions, indicating potential for further near-term gains within the top-performing Medical - Outpatient and Home Healthcare industry.

Analysis

Encompass Health (EHC) has demonstrated significant market outperformance, with its stock gaining 33.8% year-to-date to reach a new 52-week high of $123.9, substantially outpacing the broader Zacks Medical sector's -2.4% move and its direct industry's 7.9% return. This momentum is fundamentally supported by a consistent record of positive earnings surprises over the last four quarters, exemplified by its latest report where EPS of $1.40 beat the consensus estimate of $1.20. Analyst estimates project continued strength, with current fiscal year earnings expected to grow 18.28% on a 10.23% revenue increase, though this growth is forecast to decelerate to 9.26% for EPS and 8.69% for revenue in the next fiscal year. While the company's valuation presents a mixed picture—trading at a premium 23.6x forward P/E compared to the peer average of 20.5x, but at a discount on a price-to-cash flow basis at 16.3x versus the peer average of 17.9x—its Zacks Rank #2 (Buy) status, driven by favorable estimate revisions, and its position within a top-performing industry (top 23%) suggest continued investor confidence.

Key Decisions for Investors

• Given the strong earnings growth and positive analyst revisions, investors with existing positions could consider holding, but should be aware that the stock is trading at a 52-week high with a weak 'D' score for momentum, which may signal a potential for consolidation.
• Potential investors should weigh the premium forward P/E of 23.6x against the strong projected current-year EPS growth of 18.28% and the more favorable price-to-cash flow multiple of 16.3x.
• It is prudent to monitor future earnings reports to see if the company can maintain its beat-and-raise cadence, as the projected deceleration in growth for the next fiscal year is a key risk factor.
• For sector allocation, consider a comparative analysis against peers like Aveanna Healthcare (AVAH), which exhibits stronger growth and momentum scores and a lower forward P/E, to gauge relative value within the outperforming home healthcare industry.